![]() |
Name |
Vinyl carbazole
|
Molecular Formula | C14H11N | |
IUPAC Name* |
1-ethenyl-9H-carbazole
|
|
SMILES |
C=CC1=C2C(=CC=C1)C3=CC=CC=C3N2
|
|
InChI |
InChI=1S/C14H11N/c1-2-10-6-5-8-12-11-7-3-4-9-13(11)15-14(10)12/h2-9,15H,1H2
|
|
InChIKey |
APQXWKHOGQFGTB-UHFFFAOYSA-N
|
|
Synonyms |
vinyl carbazole; SCHEMBL36138; CHEMBL451160
|
|
CAS | NA | |
PubChem CID | 15114296 | |
ChEMBL ID | CHEMBL451160 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 193.24 | ALogp: | 4.2 |
HBD: | 1 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 15.8 | Aromatic Rings: | 3 |
Heavy Atoms: | 15 | QED Weighted: | 0.581 |
Caco-2 Permeability: | -4.862 | MDCK Permeability: | 0.00001260 |
Pgp-inhibitor: | 0.064 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.951 |
30% Bioavailability (F30%): | 0.467 |
Blood-Brain-Barrier Penetration (BBB): | 0.77 | Plasma Protein Binding (PPB): | 95.49% |
Volume Distribution (VD): | 0.851 | Fu: | 1.70% |
CYP1A2-inhibitor: | 0.993 | CYP1A2-substrate: | 0.76 |
CYP2C19-inhibitor: | 0.716 | CYP2C19-substrate: | 0.382 |
CYP2C9-inhibitor: | 0.632 | CYP2C9-substrate: | 0.916 |
CYP2D6-inhibitor: | 0.843 | CYP2D6-substrate: | 0.91 |
CYP3A4-inhibitor: | 0.512 | CYP3A4-substrate: | 0.273 |
Clearance (CL): | 5.034 | Half-life (T1/2): | 0.225 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.315 |
Drug-inuced Liver Injury (DILI): | 0.862 | AMES Toxicity: | 0.753 |
Rat Oral Acute Toxicity: | 0.115 | Maximum Recommended Daily Dose: | 0.729 |
Skin Sensitization: | 0.932 | Carcinogencity: | 0.832 |
Eye Corrosion: | 0.527 | Eye Irritation: | 0.994 |
Respiratory Toxicity: | 0.975 |